Primum non nocere - NICE guidelines on venous thromboembolism

Anaesthesia

Volumn 65, Issue 8, 2010, Pages 774-778

  Davies, R G ^a   Rayment, R ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A; CONTRACEPTIVE AGENT; CREATININE; DABIGATRAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; GLYCOSAMINOGLYCAN; HEPARIN; HYPERTENSIVE AGENT; RIVAROXABAN; TINZAPARIN;

ADVERSE DRUG REACTION; AGED; BLEEDING; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG MEGADOSE; EDITORIAL; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEALTH CARE PLANNING; HIGH RISK PATIENT; HIP SURGERY; HUMAN; INTENSIVE CARE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION TEST; KNEE ARTHROSCOPY; KNEE SURGERY; LENGTH OF STAY; LOW DRUG DOSE; MORBIDITY; MULTIPLE ORGAN FAILURE; OBESITY; POSTOPERATIVE THROMBOSIS; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REGIONAL ANESTHESIA; RETICULOENDOTHELIAL SYSTEM; RISK ASSESSMENT; SCREENING; STANDARDIZATION; SURGICAL PATIENT; THROMBOSIS PREVENTION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; GREAT BRITAIN; HUMANS; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 77954501408     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2010.06418.x     Document Type: Editorial

References (46)

1. Kakkar VV, Corrigan TP, Fossard DP, Sutherland I, Thirwell J. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. Lancet 1977 1 : 567 569.
2. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Annals of Surgery 1988 208 : 227 240.
3. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. New England Journal of Medicine 1988 318 : 1162 1173.
4. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American college of chest physicians (8th edition). Chest 2008 133 : 381S 453S.
5. Bergmann JF, Cohen AT, Tapson VF, et al. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE global survey. Thrombosis and Haemostasis 2010 103 : 736 748.
6. Kakkar AK, Cohen AT, Tapson VF, et al. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Annals of Surgery 2010 251 : 330 338.
7. Kahn SR, Panju A, Geerts W, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thrombosis Research 2007 119 : 145 155.
8. Amin A, Spyropoulos AC, Dobesh P, et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). Journal of Thrombosis and Thrombolysis 2010 29 : 326 339.
9. Hunt BJ. The prevention of hospital-acquired venous thromboembolism in the United Kingdom. British Journal of Haematology 2008 144 : 642 652.
10. Agency for Healthcare Research and Quality. Making health care safer. A critical analysis of patient safety practices 2001. http://archive.ahrq.gov/ clinic/ptsafety/ (accessed 27/05/2010).
11. Scottish Intercollegiate Guidelines network. Prophylaxis of venous thromboembolism 2002. http://www.sign.ac.uk/guidelines/fulltext/62/index.html (accessed 18/03/2010).
12. National Institute for Health and Clinical Excellence. Reducing The Risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism) in Inpatients Undergoing Surgery.
13. Royal College of Obstetricians and Gynaecologists. Thrombosis and Embolism During Pregnancy and the Puerperium, Reducing the Risk. (Green-Top 37) 2009. http://www.rcog.org.uk/files/rcog-corp/GT37ReducingRiskThrombo.pdf (accessed 18/03/2010).
14. Chief Medical Officer. Guidelines on the Prevention and Treatment of Venous Thromboembolism in Hospitalised Patients 2005. http://www.dh.gov.uk/prod- consum-dh/groups/dh-digitalassets/@dh/@en/documents/digitalasset/dh-4116228.pdf (accessed 18/03/2010).
15. National Institute for Health and Clinical Excellence. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. http://guidance.nice.org.uk/CG92/Guidance/pdf/ English (accessed 18/03/2010).
16. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular weight heparins in special populations. Pharmacotherapy 2001 21 : 218 234.
17. Corsonello A, Pedone C, Corica F, et al. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Archives of Internal Medicine 2005 165 : 790 795. (Pubitemid 40569433)
18. Nygaard HA, Naik M, Ruths S, Krüger K. Clinically important renal impairment in various groups of old persons. Scandinavian Journal of Primary Health Care 2004 22 : 152 156.
19. Hirsh J, Raschke R. Heparin and low-molecular weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004 126 : 188S 203S. (Pubitemid 39297954)
20. Douketis J, Cook D, Meade M, et al. Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Archives of Internal Medicine 2008 168 : 1805 1812.
21. Rabbat CG, Cook DJ, Crowther MA, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. Journal of Critical Care 2005 20 : 357 363.
22. Mahé I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thrombosis and Haemostasis 2007 97 : 581 586.
23. Rocha AT, Paiva EF, Lichtenstein A, Milani J, Cavalheiro-Filho C, Maffei FH. Risk assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. Vascular Health and Risk Management 2007 3 : 533 553.
24. Ribic C, Lim W, Cook D, Crowther M. Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review. Journal of Critical Care 2009 24 : 197 205.
25. Mayr AJ, Dunser M, Jochberger S, et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thrombosis Research 2002 105 : 201 204.
26. Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. British Journal of Haematology 2004 125 : 69 73.
27. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. British Journal of Haematology 2007 139 : 289 296.
28. Lewis G (ed). The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers' Lives: Reviewing Maternal Deaths to Make Motherhood Safer - 2003-2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom.
29. Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body weight and current doses may be inadequate in obese patients. British Journal of Surgery 2003 90 : 547 548.
30. Borkgren-Okonek APN, Hart RW, Pantano JE, et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surgery for Obesity and Related Diseases 2008 4 : 625 631.
31. Kitchen S, Lampietro R, Woolley AM, Preston FE. Anti-Xa monitoring during treatment of LMWH or danaparoid: inter-assay variability. Thrombosis and Haemostasis 1999 82 : 1289 1293.
32. Kehlet H. Fast-track colorectal surgery. Lancet 2008 371 : 791 793.
33. Sweetland S, Green J, Liu B, et al. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. British Medical Journal 2009 339 : b4583.
34. Michot M, Conen D, Holtz D, et al. Prevention of deep-vein thrombosis in ambulatory arthroscopic knee surgery: a randomized trial of prophylaxis with low-molecular weight heparin. Arthroscopy 2002 18 : 257 263.
35. Hoppener MR, Ettema HB, Kraaijenhagen RA, Verheyen CC, Henny PC. Day-care or short-stay surgery and venous thromboembolism. Journal of Thrombosis and Haemostasis 2003 1 : 863 865.
36. Ahonen J. Day surgery and thromboembolic complications: time for structured assessment and prophylaxis. Current Opinion in Anesthesiology 2007 20 : 535 539.
37. Rasmussen MS, Jørgensen LN, Wille-Jørgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database of Systematic Reviews 2009 1 : CD004318.
38. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short term enoxaparin for the prevention of venous thromboembolism after hip arthroplasty; a double blind, randomised controlled trial. Lancet 2008 372 : 31 9.
39. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 133 : 299S 339S.
40. National Patient Safety Agency. Cleanyourhands campaign. http://www.npsa.nhs.uk/cleanyourhands/ (accessed 08/02/2010).
41. Grocott MP. Improving outcomes after surgery. British Medical Journal 2010 339 : b5173.
42. National Reporting and Learning Service. WHO Surgical Safety Checklist. http://www.nrls.npsa.nhs.uk/alerts/?entryid45=59860 (accessed 08/02/2010).
43. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2009 361 : 1139 1151.
44. Schulman S, Kearon C, Kakkar AJ, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New England Journal of Medicine 2009 361 : 2342 2352.
45. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010 115 : 15 20.
46. Llau JV, Ferrandis R. New anticoagulants and regional anesthesia. Current Opinion in Anesthesiology 2009 22 : 661 666.